Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Bacterial cancer therapy in autochthonous colorectal cancer affects tumor growth and metabolic landscape
Gillian M. Mackie, Alastair Copland, Masumi Takahashi, Yumiko Nakanishi, Isabel Everard, Tamotsu Kato, Hirotsugu Oda, Takashi Kanaya, Hiroshi Ohno, Kendle M. Maslowski
Gillian M. Mackie, Alastair Copland, Masumi Takahashi, Yumiko Nakanishi, Isabel Everard, Tamotsu Kato, Hirotsugu Oda, Takashi Kanaya, Hiroshi Ohno, Kendle M. Maslowski
View: Text | PDF
Research Article Gastroenterology

Bacterial cancer therapy in autochthonous colorectal cancer affects tumor growth and metabolic landscape

  • Text
  • PDF
Abstract

Bacterial cancer therapy (BCT) shows great promise for treatment of solid tumors, yet basic mechanisms of bacterial-induced tumor suppression remain undefined. Attenuated strains of Salmonella enterica serovar Typhimurium (STm) have commonly been used in mouse models of BCT in xenograft and orthotopic transplant cancer models. We aimed to better understand the tumor epithelium–targeted mechanisms of BCT by using autochthonous mouse models of intestinal cancer and tumor organoid cultures to assess the effectiveness and consequences of oral treatment with aromatase A–deficient STm (STmΔaroA). STmΔaroA delivered by oral gavage significantly reduced tumor burden and tumor load in both a colitis-associated colorectal cancer (CAC) model and in a spontaneous Apcmin/+ intestinal cancer model. STmΔaroA colonization of tumors caused alterations in transcription of mRNAs associated with tumor stemness, epithelial-mesenchymal transition, and cell cycle. Metabolomic analysis of tumors demonstrated alteration in the metabolic environment of STmΔaroA-treated tumors, suggesting that STmΔaroA imposes metabolic competition on the tumor. Use of tumor organoid cultures in vitro recapitulated effects seen on tumor stemness, mesenchymal markers, and altered metabolome. Furthermore, live STmΔaroA was required, demonstrating active mechanisms including metabolite usage. We have demonstrated that oral BCT is efficacious in autochthonous intestinal cancer models, that BCT imposes metabolic competition, and that BCT has direct effects on the tumor epithelium affecting tumor stem cells.

Authors

Gillian M. Mackie, Alastair Copland, Masumi Takahashi, Yumiko Nakanishi, Isabel Everard, Tamotsu Kato, Hirotsugu Oda, Takashi Kanaya, Hiroshi Ohno, Kendle M. Maslowski

×

Figure 1

Oral delivery of attenuated STm reduces intestinal tumor burden.

Options: View larger image (or click on image) Download as PowerPoint
Oral delivery of attenuated STm reduces intestinal tumor burden.
(A) Sch...
(A) Schematic of AOM/DSS-induced CAC model and STmΔaroA treatment. (B) Tumor burden (number of tumors/mouse) and tumor load (cumulative tumor size per mouse, mm2) in nontreated (nt) and STmΔaroA-treated mice. n = 5 for D0 and nt groups; n = 9 for STmΔaroA-treated mice. Representative of 4 independent experiments. Female mice were used in this experiment. (C) CFU of STmΔaroA in normal (N) and tumor (T) tissue from STmΔaroA-treated mice in the CAC model. (D) Schematic of Apcmin/+ mouse STmΔaroA treatment. (E) Polyp burden and polyp size per mouse in nontreated (nt) and STmΔaroA-treated mice. Data pooled from 2 independent experiments using both male and female mice, nt n = 8 (4F, 4M), STmΔaroA-treated n = 9 (5F, 4M). Lighter shaded mice in NT and STm indicate mice used for RNA analysis in Figure 4B. (F) CFU of STmΔaroA in normal (N) and polyp (P) tissue from STmΔaroA-treated mice in the Apcmin/+ model; data are shown as mean ± SD. One-way ANOVA (B) or 2-tailed t test (E) were used; data are shown as mean ± SD.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts